0001493152-24-012133.txt : 20240401 0001493152-24-012133.hdr.sgml : 20240401 20240401064743 ACCESSION NUMBER: 0001493152-24-012133 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240329 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 24805484 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
false 0001642375 0001642375 2024-03-29 2024-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 29, 2024

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   
 

 

Item 2.02 Results of Operations and Financial Condition.

 

On March 29, 2024, Guardion Health Sciences, Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2023. The press release is furnished as Exhibit 99.1 to this current report.

 

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Additional Information and Where to Find It

 

On January 30, 2024, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Doctor’s Best Inc., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (“Activ”) for aggregate cash consideration of $17.2 million, of which $1.7 million was placed in a third-party escrow account pursuant to the terms of the Purchase Agreement. Doctor’s Best Inc. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company (“XKDW”), which is publicly listed on the Shenzhen Stock Exchange.

 

In the event that the Company’s stockholders approve the aforementioned transaction and the transaction closes, the Company would be left with minimal operations. Accordingly, the Board of Directors of the Company has determined that it is advisable and in the best interests of the Company and its stockholders to approve a voluntary dissolution and liquidation of the Company pursuant to a Plan of Liquidation and Dissolution, which, if approved, would authorize the Company to liquidate and dissolve in accordance with its terms, but such decision would be subject to the Company’s ability to abandon or delay the Plan of Liquidation and Dissolution in the event that the Board of Directors determines that another transaction would be in the best interests of the Company’s stockholders. Assuming the approval of the Plan of Liquidation and Dissolution by the Company’s stockholders, the decision as to whether or not to proceed with the dissolution and when to file the Certificate of Dissolution will be made by the Board of Directors in its sole discretion.

 

In connection with the Purchase Agreement and the proposed transactions, the Company intends to file a definitive proxy statement with the United States Securities and Exchange Commission (the “SEC”), which will be distributed to the stockholders of the Company in connection with its solicitation of proxies for the vote by its stockholders with respect to the proposed transactions and other matters as may be described in the definitive proxy statement. This press release does not contain any information that should be considered by the Company’s stockholders concerning the proposed transactions and is not intended to constitute the basis of any voting or investment decision in respect of the proposed transactions. The stockholders of the Company and other interested persons are advised to read, when available, the definitive proxy statement and any amendments thereto, and documents incorporated by reference therein filed with the SEC in connection with the proposed transactions, as these materials will contain important information about the Company, the Purchase Agreement and the proposed transactions.

 

Participants in the Solicitation

 

The Company and its executive officers, directors, other members of management, and employees may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s stockholders with respect to the proposed transactions. Information regarding the executive officers and directors of the Company is set forth in the Company’s preliminary proxy statement and will be included in the Company’s definitive proxy statement relating to the proposed transactions when it becomes available.

 

Forward-Looking Statements

 

The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

   
 

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the approval by the stockholders of the sale of Activ to Doctor’s Best Inc. and the Plan of Liquidation and Dissolution of the Company, the successful completion of the sale of Activ to Doctor’s Best Inc., the successful completion of the Company’s Plan of Liquidation and Dissolution if approved by the Company’s stockholders, the use of the proceeds received from the sale, the Company’s ability to continue to fund its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Exhibit
99.1   Press release dated March 29, 2024
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

   
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
(Registrant)
Date: April 1, 2024    
  By: /s/ Jan Hall
  Name: Jan Hall
  Title: Chief Executive Officer

 

   

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Guardion Health Sciences Announces Financial Results

for the Year Ended December 31, 2023

 

Viactiv® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022

 

HOUSTON, TEXAS – March 29, 2024 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the year ended December 31, 2023. The Company also provided a corporate update to stockholders.

 

Financial highlights for the year ended December 31, 2023 include the following:

 

  ●  Total revenue was $12,248,550 for the year ended December 31, 2023, as compared to $11,049,772 for the year ended December 31, 2022, an increase of $1,198,778, or 10.8%. The Viactiv® product line generated net revenues of $11,907,867 for the year ended December 31, 2023, as compared to $10,640,119 for the year ended December 31, 2022, an increase of $1,267,748, or 11.9%. The Viactiv® product line accounted for approximately 97.2% and 96.3% of total revenue for the years ended December 31, 2023 and 2022, respectively.
     
  ● Gross profit was $5,394,517 for the year ended December 31, 2023, as compared to $4,520,387 for the year ended December 31, 2022, an increase of $874,130, or 19.3%, which was attributable to the increase in sales from the Viactiv product line.
     
  ● Gross margin for the year ended December 31, 2023 was 44.0%, as compared to 40.9% for the year ended December 31, 2022, an increase of 3.1 percentage points, which was driven by several factors, including lower transportation costs, and higher sales in 2023.
     
  ●  Total operating expenses for the year ended December 31, 2023 were $9,730,834, as compared to $21,940,985 for the year ended December 31, 2022. The decrease was attributable to several factors, including the write-off of intangible assets at December 31, 2022, lower executive stock compensation expense, and lower consultant fees.
     
  ● Loss from operations for the year ended December 31, 2023 was $(4,336,317), as compared to $(17,420,598) for the year ended December 31, 2022.
     
  ●  Other income was $4,494,350 for the year ended December 31, 2023, as compared to $2,498,370 for the year ended December 31, 2022, primarily as a result of the non-cash gain from the change in fair value of the warrant derivative liability of $3,984,900 in 2023 as compared to $2,345,800 in 2022.

 

1
 

 

  ● As a result of the aforementioned factors, net income was $158,033 for the year ended December 31, 2023, as compared to a net loss of $(14,922,228) for the year ended December 31, 2022.
     
  ● Basic and diluted net income per share for the year ended December 31, 2023 was $0.12, as compared to basic and diluted net loss per share of $(14.15) for the year ended December 31, 2022, based on 1,270,846 weighted average common shares outstanding in 2023, as compared to 1,121,000 weighted average common shares outstanding in 2022.
     
  ● Cash used in operations for the year ended December 31, 2023 was $4,369,885, as compared to $7,446,812 for the year ended December 31, 2022. The decrease of $3,076,927 in cash used by operating activities in 2023 as compared to 2022 was primarily due to a reduction in general and administrative expenses.
     
  ● As of December 31, 2023, the Company had unrestricted cash and cash equivalents of $6,359,646, as compared to $10,655,490 for the year ended December 31, 2022.

 

Commenting on the results of operations for the year ended December 31, 2023, Jan Hall, Guardion’s President and Chief Executive Officer, said, “We are pleased with the progress made during 2023, which was driven by strong topline growth combined with improved operating margins and a reduced cash burn.”

 

Recent Developments in 2024

 

Agreement to Sell Activ Nutritional, LLC

 

On January 30, 2024, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Doctor’s Best Inc., a Delaware corporation, for the sale of all of the outstanding equity interests of Activ Nutritional, LLC (“Activ”) for aggregate cash consideration of $17.2 million, of which $1.7 million was placed in a third-party escrow account pursuant to the terms of the Purchase Agreement. Doctor’s Best Inc. is a wholly-owned subsidiary of Kingdomway USA Corp., the U.S. subsidiary holding company of Xiamen Kingdomway Group Company (“XKDW”), which is publicly listed on the Shenzhen Stock Exchange.

 

The sale of Activ, as contemplated by the Purchase Agreement, is conditioned upon receiving approval from the Company’s stockholders as the sale of Activ, which owns the Viactiv® brand and business and accounted for 97.2% and 96.3% of revenues during the years ended December 31, 2023 and 2022, respectively, constitutes a sale of substantially all of the Company’s assets and revenue-generating operations. The transaction contemplated by the Purchase Agreement is the result of a broad review of strategic alternatives by the Company’s Board of Directors. The Board of Directors has determined that it is advisable and in the best interests of the Company and the Company’s stockholders to approve this transaction.

 

2
 

 

Potential Dissolution

 

In the event that the Company’s stockholders approve the transaction and the transaction closes, the Company would be left with minimal operations. The Board of Directors has additionally determined that it is advisable and in the best interests of the Company and its stockholders to approve a voluntary dissolution and liquidation of the Company pursuant to a Plan of Liquidation and Dissolution, which, if approved, would authorize the Company to liquidate and dissolve in accordance with its terms, but such decision would be subject to the Company’s ability to abandon or delay the Plan of Liquidation and Dissolution in the event that the Board of Directors determines that another transaction would be in the best interests of the Company’s stockholders. Assuming the approval of the Plan of Liquidation and Dissolution by the Company’s stockholders, the decision as to whether or not to proceed with the dissolution and when to file the Certificate of Dissolution will be made by the Board of Directors in its sole discretion.

 

On March 15, 2024, the Company filed a preliminary proxy statement with the United States Securities and Exchange Commission (the “SEC”) in order to solicit the approval of the Company’s stockholders in connection with the sale of Activ and the Plan of Liquidation and Dissolution. The Company has set May 23, 2024 as the date of the special meeting (the “Special Meeting”) of its stockholders to vote on these transactions (and the other matters as will be described in the definitive proxy statement), and the close of business on April 5, 2024 as the record date for stockholders entitled to notice of and to vote at the Special Meeting.

 

Financial Results

 

Additional information with respect to the Company’s business, operations and financial condition as of and for the year ended December 31, 2023 is contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which has been filed with SEC at www.sec.gov.

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. (Nasdaq: GHSI) is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.

 

Additional Information and Where to Find It

 

In connection with the Purchase Agreement and the proposed transactions, the Company intends to file a definitive proxy statement with the SEC, which will be distributed to the stockholders of the Company in connection with its solicitation of proxies for the vote by its stockholders with respect to the proposed transactions and other matters as may be described in the definitive proxy statement. This press release does not contain any information that should be considered by the Company’s stockholders concerning the proposed transactions and is not intended to constitute the basis of any voting or investment decision in respect of the proposed transactions. The stockholders of the Company and other interested persons are advised to read, when available, the definitive proxy statement and any amendments thereto, and documents incorporated by reference therein filed with the SEC in connection with the proposed transactions, as these materials will contain important information about the Company, the Purchase Agreement and the proposed transactions.

 

3
 

 

Non-Solicitation

 

This press release is not considered solicitating material with respect to a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transactions, and shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

 

Forward-Looking Statement Disclaimer

 

The matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the successful completion of the sale of Activ to Doctor’s Best Inc., the use of the proceeds received from the sale, the Company’s ability to continue to fund its operations, including its ocular healthcare business, subsequent to the sale, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

For more information about Guardion Health Sciences, Inc., Contact:

 

investors@guardionhealth.com

Phone: 1-800 873-5141 Ext 208

 

4

 EX-101.SCH 3 ghsi-20240329.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20240329_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20240329_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover
Mar. 29, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 29, 2024
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ghsi-20240329.xsd ghsi-20240329_lab.xml ghsi-20240329_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20240329", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "ghsi-20240329.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ghsi-20240329_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20240329_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://guardionhealth.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-03-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://guardionhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-24-012133-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-012133-xbrl.zip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form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2024-03-29 2024-03-29 iso4217:USD shares iso4217:USD shares false 0001642375 8-K 2024-03-29 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false true false false Common Stock, par value $0.001 per share GHSI NASDAQ true false